Edit |   |
---|---|
Antigenic Specificity | HSP91 homolog, Candida albicans (Efungumab biosimilar) |
Clone | Efungumab |
Host Species | Recombinant |
Reactive Species | n/a |
Isotype | scFv-heavy kappa |
Format | scFv fragment |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | FCM, IP, ELISA, Neut, FuncS, IF, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Candida Albicans HSP91 Homolog Recombinant Antibody. Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. |
Immunogen | n/a |
Other Names | Anti-HSP91 Homolog Recombinant Antibody, Research Grade Efungumab, Anti-Candida Albicans HSP91 Homolog Recombinant Antibody, HSP90mab, Mycograb, Antibody Drug Analogues, Monoclonal Antibody, YR1109, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 762260-74-2 |
Catalog # | YR1109 |
Price | please inquire |
Order / More Info | HSP91 homolog, Candida albicans (Efungumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |